Migdal Insurance & Financial Holdings Ltd. Arcutis Biotherapeutics, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 02, 2022	SELL	$14.38 - $22.79 $3,781 - $5,993	-263 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$14.98 - $25.5 $2,366 - $4,029	-158 Reduced 37.53%	263 $5,000
Q3 2021 Nov 16, 2021	BUY	$19.28 - $27.1 $8,116 - $11,409	421 New	421 $10,000

Others Institutions Holding ARQT

# of Institutions

197

Shares Held

129M

Call Options Held

738K

Put Options Held

82K

Jennison Associates LLC

11.7M
Shares

$175 Million
0.07% of portfolio
Rubric Capital Management LP New York, NY

11M
Shares

$164 Million
2.84% of portfolio
Suvretta Capital Management, LLC New York, NY

10.7M
Shares

$161 Million
3.92% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

8.79M
Shares

$132 Million
4.4% of portfolio
Black Rock Inc. New York, NY

8.62M
Shares

$129 Million
0.0% of portfolio

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $902M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account